Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/20/2021 10/21/2021 10/22/2021 10/25/2021 10/26/2021 Date
74.98 74 70.81 69.15 69.15 Last
2404557 2316136 6095862 4337009 2724654 Volume
-1.47% -1.31% -4.31% -2.34% 0.00% Change
Estimated financial data (e)
Sales 2021 3 914 M 613 M 613 M
Net income 2021 1 419 M 222 M 222 M
Net Debt 2021 - - -
P/E ratio 2021 27,3x
Yield 2021 -
Sales 2022 4 444 M 696 M 696 M
Net income 2022 1 604 M 251 M 251 M
Net Debt 2022 - - -
P/E ratio 2022 24,2x
Yield 2022 -
Capitalization 38 830 M 6 083 M 6 084 M
Capi. / Sales 2021 9,92x
Capi. / Sales 2022 8,74x
Nbr of Employees 2 934
Free-Float 16,1%
More Financials
Company
Gan & Lee Pharmaceuticals Co Ltd is a company engaged in research and development, production and sales of insulin and related products. The Company's main products are insulin preparations and insulin dry powder, including Changxiulin recombinant insulin glargine injection and Suxiulin recombinant insulin lispro injection. It is also involved in the development and sales of a type of insulin pen called Xiulin Pen... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Gan & Lee Pharmaceuticals.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GAN & LEE PHARMACEUTICALS.
10/14GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
08/26Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
07/02GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
07/02Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
04/29Gan & Lee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ende..
CI
04/14Gan & Lee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended De..
CI
04/06GAN & LEE PHARMACEUTICALS : & Lee Pharma's Tumor Drug Wins Orphan Drug Designation in Euro..
MT
03/21GAN & LEE PHARMACEUTICALS CO., LTD.( : 603087) added to FTSE All-World Index
CI
01/29FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, fo..
CI
2020GAN & LEE PHARMACEUTICALS CO., LTD.( : 603087) added to S&P Global BMI Index
CI
2020GAN & LEE PHARMACEUTICALS CO., LTD.( : 603087) added to Shanghai Stock Exchange 180 Value ..
CI
2020GAN & LEE PHARMACEUTICALS CO., LTD.( : 603087) added to Shanghai Stock Exchange Health Car..
CI
2020GAN & LEE PHARMACEUTICALS CO., LTD.( : 603087) added to SSE 180 Index
CI
2020Gan & Lee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended ..
CI
2020Gan & Lee Pharmaceuticals Co., Ltd. Announces Earnings Results for the First Half of 20..
CI
More news
News in other languages on GAN & LEE PHARMACEUTICALS.

- No features available -

More news
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 69,15 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-47.70%6 081
CSL LIMITED4.53%100 969
WUXI BIOLOGICS (CAYMAN) INC.16.73%64 238
SAMSUNG BIOLOGICS CO.,LTD.6.42%49 692
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.24%40 230